This is the published version


Available from Deakin Research Online

http://hdl.handle.net/10536/DRO/DU:30072823

Reproduced with the kind permission of the copyright owner

Copyright: 2015, Korean College of Neuropsychopharmacology
Tobacco Use in Bipolar Disorder

Daniel Thomson1, Michael Berk2,3,4, Seetal Dodd2,4, Marta Rapado-Castro5,6,7, Shae E. Quirk2, Pernille K. Ellegaard8, Lesley Berk9, Olivia M. Dean2-4

1Department of Applied Sciences, RMIT, Bundoora, 2IMPACT Strategic Research Centre, School of Medicine, Deakin University, Barwon Health, Geelong, 3Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, 4Department of Psychiatry, University of Melbourne, Parkville, 5Orygen Youth Health Research Centre, Centre for Youth Mental Health, University of Melbourne, Victoria, 6Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Victoria, Australia, 7Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, CIBERSAM, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain, 8Research Unit, Mental Health Services, Region of Southern Denmark, Esbjerg, Denmark, 9Centre for Mental Health and Wellbeing Research, School of Psychology, Deakin University, Burwood, Australia

Tobacco use in mental health in general and bipolar disorder in particular remains disproportionally common, despite declining smoking rates in the community. Furthermore, interactions between tobacco use and mental health have been shown, indicating the outcomes for those with mental health disorders are impacted by tobacco use. Factors need to be explored and addressed to improve outcomes for those with these disorders and target specific interventions for people with psychiatric illness to cease tobacco smoking. In the context of bipolar disorder, this review explores: the effects of tobacco smoking on symptoms, quality of life, suicidal behaviour, the biological interactions between tobacco use and bipolar disorder, the interactions between tobacco smoking and psychiatric medications, rates and factors surrounding tobacco smoking cessation in bipolar disorder and suggests potential directions for research and clinical translation. The importance of this review is to bring together the current understanding of tobacco use in bipolar disorder to highlight the need for specific intervention.

KEY WORDS: Bipolar disorder; Smoking; Smoking cessation; Quality of life; Psychotropic drugs.

INTRODUCTION

Tobacco smoking is a leading preventable cause of poor health and premature mortality.1 While tobacco smoking rates in the general population are declining, they remain raised in cohorts with psychiatric problems.2 Nicotine, the primary active compound found in tobacco, is highly addictive.3 High rates of tobacco smoking have been described in bipolar disorder and are associated with poorer outcomes.4 Tobacco smoking is approximately 2-3 times more prevalent in bipolar disorder than in the general population, with estimates ranging from 60-70% in bipolar patients compared to 25-30% in the general population.2,4,5 This elevated smoking rate may not only impact on the course of the disorder but may also contribute to higher levels of tobacco-related morbidity and mortality.6

Despite high rates of comorbidity and related morbidity, there is a only modest field of research focusing on smoking among individuals with bipolar disorder and the relationship with important clinical and public health outcomes including: the effects on mood symptoms, quality of life, suicidal behaviour, implications for pharmacological treatment, barriers to cessation, and the biological pathways modulating the expression of pathophysiology. Moreover, results from existing studies spanning these topics appear conflicting, suggesting uncertainty exists in the literature.

Some authors have argued that tobacco smoking results in poorer treatment outcomes in bipolar disorder,7-12 whereas other researchers have not found such a relationship.13,14 Variance between studies may be due to design factors including the sample size, the sample selection inconsistent measurements of smoking behaviour, and the methodological design of the studies. Given this, the following review aims to explore the issues specific to smoking cessation in bipolar disorder and provide the most clarity regarding treatment options and outcomes.

A comprehensive search using PubMed and Google
Scholar was conducted using the terms “smoking and mania”, “smoking and bipolar disorder” and “nicotine dependence and bipolar disorder”. The purpose of the current review was to explore the effects of tobacco smoking in bipolar disorder, examining the relationship between smoking and mood symptoms (e.g., depression and mania), quality of life, suicidal behaviour, biological interactions between the pathophysiology of the disorder and the addiction to tobacco, as well as the effects of tobacco smoke on medication and of smoking cessation. Specifically, this paper discusses pertinent studies spanning clinical and public health topics, addressing current gaps in the field and extending previous reviews conducted, with an aim of prompting further research in the nascent field. Such an evidence base may also provide a context for guiding policy makers and informing clinical practice.

MAIN SUBJECTS

Tobacco Smoking Cessation and Effects on Mood Symptoms

At a population level, mood symptoms such as mania or depression appear to be associated with tobacco use. The presence of mania and hypomania is associated with 3.9 and 3.5 times greater likelihood of tobacco dependence in the psychiatric population, respectively.15) Additionally, during acute tobacco smoking cessation, those with bipolar disorder may have higher risks of experiencing mania16,17) and transient depressive recurrence.18) Furthermore, Adan et al.19) have reported low mood scores in highly dependent smokers, intermediate mood scores in low dependent smokers and high mood scores in non-smokers, suggesting the role nicotine dependence plays in mood regulation. Another issue regarding bipolar disorder and tobacco smoking cessation is the potential effect of cessation on mood symptoms. Although there have been case reports of mania,16,17) and depression,18) following abrupt nicotine withdrawal, there are few double blind placebo controlled studies that have looked at the effect of tobacco cessation on mood. A key recent meta-analysis has shown that on aggregate, mental health symptoms, particularly depression, improve in those who quit smoking.20)

Those with bipolar disorder might thus be proposed to have an increased susceptibility to tobacco smoking despite the observation that many patients start to smoke before the onset of their illness.21-23) Research shows that most smokers take up the habit as teenagers,24) with recent statistics in Australia revealing that in 2010, the age of initiation was 16.25) Regarding the age of onset in bipolar disorder, for bipolar type I the average age of onset is 23 years for males and 26 years for females, and for bipolar type II, the age of onset is 29.7 years for males and 30.1 years for females.26) A line of research has postulated that enduring alterations in neurophysiology as a result of tobacco abuse may unmask an underlying vulnerability to affective disorders, including bipolar disorder.19,27,28) However, the mechanisms underlying the relationship between tobacco smoking and bipolar disorder are clearly bidirectional, complex and multifactorial.13,29) Therefore, while it is probably correct that in most instances tobacco smoking behaviour pre-dates and is a risk factor for bipolar disorder, caution is recommended when interpreting these findings and implying causality.

Specific associations between tobacco smoking status and symptom characteristics of the disorder have been described.7,8,11,12,30,31) In an early study looking at the role of tobacco smoking and psychotic symptom status in bipolar disorder, Corvin et al.12) examined the effect of smoking severity on a sample of 92 patients with bipolar disorder. Tobacco smoking was less prevalent in less symptomatic patients whereas pervasiveness of smoking was correlated with severity of symptoms (particularly psychotic symptoms). This was a cross-sectional study with a small sample size using self-report measures which should be noted when interpreting the results, as no objective measure such as blood test were used to detect nicotine use. A recent prospective and naturalistic study over 24 months examined the effect of tobacco smoking on mental health outcomes in 239 patients with schizoaffective and bipolar disorder,11) and found that in both schizoaffective and bipolar disorder, daily smokers had poorer prognosis in terms of depression and overall bipolar symptomatology (assessed using the Clinical Global Impressions—Depression and Clinical Global Impressions—Overall Bipolar scales) and longer stays in hospital compared with non-smokers. An important limitation, similar to Corvin and colleagues,12) is that the study did not objectively measured nicotine dependence and used self-report measures. This is again an important issue as varying levels of nicotine dependence may affect overall scores and mood symptomatology more than simply assessing daily smoking rates reported by the patients. Daily smoking rates do not necessarily address smokers’ levels of nicotine addiction amongst patients with bipolar disorder.

Other studies have reported a link between tobacco smoking and worse outcomes in both mania and depression in bipolar disorder.7,8,16,30,31) In particular, a large
study of 399 patients with bipolar disorder reported that a lifetime history of tobacco smoking was significantly related to earlier onset of the first depressive or manic episode, greater symptom severity, poorer functioning, a lifetime history of suicide attempt comorbid anxiety and substance abuse. In addition, results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) have linked tobacco smoking to clinical variables including more lifetime manic and depressive symptoms, rapid cycling illness, comorbid mental disorders, substance abuse and active illness. However cross-sectional studies have showed inconsistent findings. In the most recent study, illness severity, number of episodes, history of psychotic symptoms, history of suicide attempts, age at onset of the illness, abuse of psychoactive drugs, current clinical status and other demographic variables and their relationship with tobacco smoking were examined in a sample of 102 participants with bipolar disorder. There was a higher tobacco smoking prevalence in this population and a higher presence of alcohol and other drugs use and earlier age of illness onset in those patients with bipolar disorder who smoked more. No other association with regard to illness severity was found in this study. However, the authors caution against generalisation due to the small sample size and the cross sectional study design. Furthermore, nicotine levels were not measured in this study. Similarly, Cassidy et al. reported no association between smoking and psychosis in patients with bipolar disorder, but no measures of mood were included in the analysis.

Inconsistent findings on the impact of tobacco smoking on prognosis in bipolar disorder have also been recently reported in a comprehensive review on the effects of smoking on the health outcomes in bipolar disorder. In the reviewed studies, tobacco smoking was correlated with rapid cycling, more affective episodes, elevated risk of psychotic episodes, and more time spent in hospital, in some studies but not in others. Individual differences in nicotine dependence may account for the variability of the findings between studies. Methodological complexities including limited number of participants, bipolar patients who are nicotine dependent versus smokers who are non-nicotine dependent, admixtures of prospective and cross-sectional studies, diverse measures and lack of objective biological markers might account for the difference observed.

**Quality of Life and Tobacco Smoking in Bipolar Disorder**

Tobacco use enhances mortality and decreases quality of life through a number of smoking-related health diseases such as cardiovascular, cancer or respiratory conditions. Tobacco smoking has also been related to more severe course, relapse and higher number of hospitalizations, and is also associated with an elevated risk of concomitant substance use disorders. Few studies have examined the quality of life in smokers versus non-smoker with bipolar disorder. Consistent findings across studies have shown that quality of life is higher in non-smokers and occasional smokers compared with nicotine dependent bipolar patients. Smoking has also been associated with low socioeconomic status in patients with bipolar disorder, and with the risk of anxiety disorders in the general population, which may be moderating or mediating pathways.

In a study examining the quality of life in bipolar disorder in comparison with that of the general population, 48 euthymic and 60 non-euthymic bipolar patients were compared with 1210 controls using the physical and mental component scores of the Medical Outcomes Survey 36-item Short Form Health-Survey (SF-36). Clinical and course of illness variables and their association with low physical and mental quality of life were explored including manic and depressive symptoms and consumption of other addictive substances. Lower mental quality of life was associated with longer duration of illness and early onset in bipolar patients. A higher presence of depressive symptoms, nicotine dependence and lack of social support was also reported in the bipolar group. Further studies have replicated this association. Quality of life in terms of physical health, psychological wellbeing and environmental and social relationships was lower in bipolar patients with nicotine dependence than in those without nicotine dependence. Further health related quality of life scores were also found for daily smokers. It is plausible that tobacco smoking in bipolar disorder might be indirectly influencing this construct through modifiable lifestyle factors that have also shown to be related to bipolar disorder. Poorer diet and lower levels of physical activity have been associated with smokers, in addition to these factors already being present in bipolar disorder. Furthermore, tobacco smoking may play a detrimental role in sleep quality for those with bipolar disorder. Sleep disturbance has comprehensively and independently been associated with poor health-related quality of life. In a study including 252 participants with mood disorder, the severity of the disorder was positively associated with the mean number of cigarettes smoked per day and with greater levels of fatigue. Additionally, mild
to severe symptoms of insomnia were related to the level of nicotine dependence. Differences between smokers and non-smokers in circadian rhythmicity and mood variation have been reported in the general population. Altered sleep patterns play a detrimental role in bipolar disorder, as disrupted night time sleep and day time mood have been proposed to be mutually reinforcing. This bidirectional model, known as the sleep-mood cycle, is of particular importance to bipolar disorder and insomnia. Disruptions in circadian rhythms have been identified as a major trigger for the onset and relapse of bipolar disorder. These modifiable lifestyle factors not only play a role in quality of life for bipolar disorder, but these relationships imply that they could play a critical part in the management of the illness.

The Relationship between Tobacco Smoking and Suicidal Behaviour in Bipolar Disorder

To date, many studies have identified associations between psychiatric disorders, comorbidities and suicide attempts. This has been demonstrated across several studies utilizing adequate study designs with large sample sizes. In particular, tobacco smoking has also been independently linked to increased risk of suicidality, an association that was sustained after adjustment for psychiatric disorders.

Individuals with bipolar disorder, have higher rates of suicide than the general population. Moreover, the contribution of disability and mortality related to physical causes of death, suicide and injuries incurred via self-harm in this group are significant. Due to the deleterious outcomes for individuals and significant burden that both tobacco smoking and suicidal behaviour incurs, it is necessary to understand the role of this potentially modifiable lifestyle factor and its link to suicidal behaviour in this group to reduce mortality and disability.

Several studies have demonstrated associations between tobacco smoking in bipolar disorder and suicidal behaviour. In one study, predictors of suicidal acts were investigated in a 2-year follow-up study of patients presenting with major depressive disorder or bipolar disorder at baseline. Cox proportional hazards regression analyses revealed that tobacco smoking was among the strongest predictors for future suicidal acts, alongside history of suicidal acts and self-reported severity of depression. Furthermore, among other significant clinical predictors for suicidal acts were presence of a comorbid Cluster B personality disorder, and aggressive and impulsive personality traits. These personality features and traits have been shown to be risk factors for self-mutilation, help-seeking suicide threats and/or attempts and completed suicide, and frequently co-occur with bipolar disorder. It is possible that comorbidity among impulsive/aggressive features and smoking increases the risk for suicidal behaviours in bipolar disorder.

A retrospective clinical study also demonstrated significant associations between lifetime tobacco smoking and suicide attempts in patients with bipolar disorder, after adjusting for other psychiatric comorbidities and measures of disability and functional impairment. Finally, subsequent prospective analyses have also reported that tobacco smoking was associated with increased risk of suicidality in individuals with bipolar disorder, throughout the course of a nine-month follow-up. These baseline associations were not sustained after adjustment for impulsivity in the models. Moreover, small sample sizes precluded further analyses examining associations between impulsivity, smoking and suicide attempts.

The increased risk for suicide attempts among those with bipolar disorder, and who smoke, appears to true even for youths. The Course and Outcome of Bipolar Youth Study examined 212 youths (7-17 years) with bipolar disorder and correlates. Differences between three groups of tobacco smoking status (daily, never smoked, ever smoked) were observed, with daily smokers having a higher lifetime prevalence of suicide attempts. Logistic regression found those with a history of tobacco smoking had approximately a three-fold increased risk of lifetime suicide attempt compared to those without. However, it was beyond the scope of the study to examine the prevalence and correlates of nicotine dependence among the youths with bipolar disorder. Further, longitudinal analyses of subsequent follow-up visits may elucidate temporal relationships smoking and suicidality in the younger with bipolar disorder.

Contrary these findings, others have reported no significant associations for tobacco smoking and suicidality in bipolar disorder in longitudinal analyses. In one study, 40.5% of those who had attempted and/or completed suicide over the observational period (2 years) were smokers. Whilst there was an initial trend for associations between baseline tobacco smoking status and increased risk for suicide attempts, the association was not sustained in logistic regression models, as was the case in another study with a similar follow-up period. An additional prospective study also reported that tobacco smoking did not predict suicide attempts over the ob-
sorvational period (18 months). A review examining the clinical and health outcomes of a number of psychiatric disorders, also suggested that associations between tobacco smoking and suicidal behaviour in patients with bipolar disorder was inconclusive.

These studies highlight that tobacco smoking may be independently associated with suicide attempts in individuals with bipolar disorder. However, there remains areas of uncertainty about the relationship between tobacco smoking and bipolar disorder in regards to suicidal behaviour. It may be that personality variables (linked to impulsivity) may be important effect modifiers in the relationship between tobacco smoking and suicidality, particularly during acute phases of the disorder. Examining the potential role of personality as a mediating and/or moderating variables in future studies examining tobacco smoking and comorbidities is warranted.

**Biological Interactions between the Pathophysiology of Bipolar Disorder and Tobacco Addiction**

To date, operative mechanisms linking tobacco smoking and bipolar disorder remain unclear. In unipolar depression, the role of neurotransmitters has been hypothesized. Associations may be related to lower levels of brain serotoninergic function in smokers. Lower levels of serotonin in both humans and primates have been linked with higher levels of depressive, novelty seeking behaviour. However, given discrepancies between the underlying biology in unipolar and bipolar depression (see next section), caution needs to be taken when considering these links. Additionally, dysregulation of the dopaminergic and glutamatergic systems and their inputs to different regions of the brain (particularly prefrontal cortex and basal ganglia) have been linked to the maintenance and relapse of addictive behaviour. Nicotine is a nicotinic cholinergic receptor agonist that causes the release of both dopamine and norepinephrine. These two neurotransmitters are implicated in the pathophysiology of bipolar disorder, and are also thought to play a key role in addiction. This may influence susceptibility of people with bipolar disorder to the rewarding effects of nicotine. Furthermore, smokers have reduced monoamine oxidase which is a potential pharmacological effect of tobacco smoke as it prolongs the synaptic presence of neurotransmitters involved in mood regulation (i.e., serotonin and dopamine). Cholinergic- monoamine pathway interactions may link nicotine dependence and bipolar disorder given the putative role of dopamine, serotonin noradrenaline and glutamine in the pathogenesis of both bipolar disorder and nicotine addiction and the role of monoamine neurotransmitters in mood disorders.

In this regard, cyclical dopamine dysregulation has been proposed as a central mechanism underlying bipolarity. The activation of the mesolimbic dopaminergenic pathways through the diffuse cholinergic innervations in the brain is thought to play a salient role in the generation of reward and reinforcement of tobacco smoking. Further to this, dynamic desensitization of nicotinic cholinergic, dopaminergic and other downstream receptors may account not only for nicotine tolerance and withdrawal symptoms but also for smoking conditioning through the rewarding effects of nicotine in the brain. An increase in dopaminergic transmission would predominate during the manic phase there is whereas a secondary down regulation of receptors would eventually dampen the cycle learning to a phase of decreased dopaminergic transmission, characteristic of the depressive phase. This theory of the role of the dopaminergic system provides support for the relationship between tobacco smoking and mood disorders. There might be a number of other underlying neurobiological mechanisms to account for this relationship given the vast array of other neurochemicals triggered by nicotine. Enduring changes in excitatory glutamatergic synapses on the nucleus accumbens are induced by nicotine use, and have been shown to be involved in drug relapse. Recently, disturbances in glutamatergic function have also been implicated in the pathophysiology of mood disorders (major depressive disorder and bipolar disorder). The role of inflammation and oxidative and nitrosative stress as a plausible mediator for the development of depressive and bipolar disorders and its relationship to tobacco use have also been examined in recent years. The literature also provides some support for a potential interaction between tobacco smoking and the neuroprogressive course of the disorders as these pathways are affected by exposure to tobacco smoke components such as nicotine and free radicals.

**Effects of Tobacco Smoking on Pharmacological Treatment in Bipolar Disorder**

The effect of tobacco smoking on the impact of the metabolism of many psychotropic medications used in the treatment of bipolar disorder is well documented. Polycyclic aromatic hydrocarbons in tobacco smoke, increase the metabolism of some psychotropic medications, including olanzapine, clozapine, haloperidol and fluvoxamine. This is largely mediated via the induction of the
hepatic cytochrome P450 enzyme 1A2 by the polycyclic aromatic hydrocarbons found in tobacco smoke, leading to lower serum levels of drugs including olanzapine as well as other antipsychotics, antidepressants and benzodiazepines. This may be a pathway whereby tobacco smoking reduces the therapeutic benefits of taking these medications. This results in smokers with bipolar requiring an increased dose, approximately 50% higher, to achieve an adequate therapeutic response.67)

Additionally, some case reports suggests that a substantial increase in tobacco smoking can lead to an increase in psychiatric symptoms among individuals with bipolar disorder who are taking olanzapine, at least in part due to the reduction in medication levels explored the dose dependent effect of tobacco smoking on serum concentrations of clozapine and olanzapine.67) The mean serum concentration to dose ratio was twice as high in non-smokers compared to smokers for both olanzapine and clozapine, leading to authors to consider differential starting doses in smokers compared to non-smokers.

It has been further reported that nicotine’s activation of the sympathetic nervous system may reduce the sedating effects of benzodiazepines and the capacity of beta blockers to lower heart rate and blood pressure.4) The evidence that tobacco smoking not only interferes with a range of different medications, points to the widespread effect that nicotine and tobacco smoke plays on multiple neurotransmitter and brain systems.11,67–69) Dani and De Biasi68) suggest fast nicotinic transmission is used throughout the peripheral nervous system and at the neuromuscular junctions, leading to body-wide impacts. This view is supported by Laviolette and van der Kooy,69) who state that nicotine produces diverse neurophysiological, motivational and behavioural effects throughout several brain regions via multiple neurochemical pathways.

The far-reaching ability of nicotine to produce changes in multiple neurotransmitter systems is possibly through the widespread cholinergic innervations that nicotine plays on the brain. As nicotine is a nicotinic cholinergic receptor agonist it enhances the release of a cascade of neurotransmitters including dopamine, serotonin, norepinephrine and glutamate. Agents that drive dopamine such as non-selective α2-adrenoceptor agonist it enhances the release of a cascade of neurotransmitters.61) Nicotine may thus indirectly drive dopamine itself as well as counteract the effects of pharmacological interventions, firstly via its psychostimulant properties, and secondly via pharmacokinetic interactions as highlighted above.

Hutchison et al.70) looked at the atypical antipsychotic, olanzapine, in attenuating cue elicited craving for tobacco. The hypothesis was that if mesolimbic dopaminergic activity is associated with cue-elicited cravings for tobacco, a dopaminergic antagonist should attenuate cue-elicited cravings for tobacco. Olanzapine attenuated cue elicited craving for tobacco, but did not moderate the subjective effects of tobacco smoking in a randomly assigned five day placebo controlled trial. However, dopamine antagonists decrease the pleasure, reinforcement and reward of tobacco smoking, which might lead to increase smoking behaviour.71)

### Tobacco Smoking Cessation and Bipolar Disorder

The rate of successful cessation attempts for people with mental illness is low. Data from the United States 2002 National Survey on Drug Use and Health demonstrated that the quit rate was 49% for former smokers with no serious psychological distress, determined using the K6 scale, whereas the quit rate was 29% for former smokers with serious psychological distress.72) The reason for these reduced quit rates has been examined by tobacco control researchers, with one view describing the concept of ‘hardening’ and ‘hard-core smokers’, where reduced quit rates are attributed to greater difficulty in quitting or less willingness to do so.73) In the general population, evidence of hardening remains elusive as tobacco smoking rates continue to decline; however, amongst people with bipolar and other major psychiatric disorders smoking rates have not declined at the same rate and hardening may be a factor. However, it is very unlikely to fully explain the disparity in quit rates between the mentally ill and general populations. Smokers with mental illness may be as motivated to quit smoking tobacco as smokers without a current mental illness. This has been demonstrated in studies of an inpatient population58) in Australia. There is some data indicating less readiness to quit amongst bipolar patients in India54), however, this may be attributed to a lesser awareness of the health risks of tobacco smoking in that specific population. This suggests that willingness to quit may not be a factor in the discrepancies between quit rates between mentally ill and not mentally ill smokers. Greater difficulty in quitting smoking may still be a ‘hardening’ factor in this population as most readily available tobacco smoking cessation strategies have been developed for the general population and may not be as effective for mentally ill smokers.

Other non-hardening factors may also be applicable to
this population, including less awareness of the health risks associated with tobacco smoking, a factor likely to vary considerably between and even within different countries. There are reports that some people with mental illness may feel alienated from approaching mainstream tobacco smoking cessation services. However, the reasons for the disparity in smoking cessation rates between mentally ill and not mentally ill people have not been sufficiently researched.

In a review of tobacco smoking cessation in bipolar disorder, George et al. found just 11 clinical studies on bipolar disorder and tobacco addiction showing that people with bipolar disorder have much lower quit rates than smokers without a comorbid condition. Several case reports as reviewed by Dome et al. suggested that varenicline treatment, for tobacco cessation, may provoke mania in patients with or without a history mood disorders. However this has not been borne out by large scale well designed randomized trials.

There have only been four published controlled smoking cessation treatment studies in bipolar smokers. The first two are relatively small studies, with two recent more definitive studies with varenicline. The initial small pilot study (n=5) but showed bupropion was well-tolerated and potentially useful during 10 weeks of treatment. Following on from this, Wu et al. conducted another tiny (n=5) study of varenicline for tobacco cessation in those with bipolar disorder. Over the 10-week treatment phase, reduction in tobacco smoking in the varenicline group was found and it was well tolerated. In the first large randomized controlled trial of varenicline for tobacco cessation maintenance in individuals diagnosed with bipolar disorder and schizophrenia, 87 participants were included in the maintenance phase, of which only 13 were diagnosed with bipolar disorder (the remaining were diagnosed with schizophrenia). The study included an open-label phase for 12 weeks following which participants who were abstinent for at least 14 days were then randomized to receive either continued varenicline treatment, or placebo up to 52 weeks of treatment. Varenicline was efficacious as a maintenance treatment in the study, and this effect remained when those with bipolar disorder were analysed separately. The largest and most rigorous study was that by Evins et al., who enrolled 247 smokers with schizophrenia or bipolar disorder from 10 community mental-health centres. Of these, 203 received 12-week treatment with both open-label varenicline and cognitive behavioral therapy, after which 87 met abstinence criteria and entered the relapse prevention intervention. After a year, the point-prevalence abstinence rates were 60% with varenicline treatment and 19% with placebo, giving an odds ratio of 6.2. Importantly, there were no impacts on psychiatric symptoms.

This paper has highlighted that tobacco smoking is deleterious to mental health, but a critical question is whether mental health benefits from tobacco smoking cessation. A critical review and meta-analysis has recently been published, with striking findings. Firstly, quitting has been linked to reduced anxiety and stress, depression, and improved positive mood as well as quality of life compared with ongoing tobacco smoking. Secondly, effect sizes are equivalent for people with psychiatric disorders compared to those without. Lastly, effect sizes appear similar or greater than those of antidepressant treatment for the abovementioned disorders. This finding highlights the necessity to work towards cessation.

It is not clear how best to assist smokers with mental illness to quit tobacco smoking. There are additional factors that may further contribute to the success or failure of smoking cessation in those particularly, diagnosed with bipolar disorder. Given the high rates of comorbid anxiety disorders and substance abuse the complexities of treatment for smoking cessation are increased. George et al. have suggested that the alternating mood fluctuations (ranging from irritable and elevated mood to severe depression) may contribute to differences in smoking cessation rates found in bipolar disorder. Similarly, Ostacher et al. reported a relationship between comorbid anxiety disorders and substance abuse in lifetime smokers with bipolar disorder, suggesting further difficulty in smoking cessation. Current smoking cessation interventions for individuals with bipolar disorder include several first line pharmacotherapies that include nicotine replacement therapy, bupropion, sustained release and varenicline. It has also been reported that olanzapine can assist in cue prompted cravings for tobacco. The problem with most of these therapies is that it is unclear how safe and efficient these aids are for people with bipolar disorder. Unlike pharmacotherapy, behavioural interventions have been tested but unfortunately, current evidence is insufficient to recommend these approaches as alternatives to standard counselling. However, behavioural interventions improve the chances of quitting, especially when used in conjunction with pharmacotherapy. Examples of behavioural interventions include cognitive behaviour therapy, mood management interventions and motivational interviewing.

Most large studies use mixed populations that are gen-
erally heavily weighted towards high prevalence disorders. El-Guebaly et al. reviewed 24 studies of tobacco smoking cessation in people with mental disorder, where the majority of interventions combined pharmacotherapies and psychoeducation, and found that quit rates for people with mental illnesses were similar to those expected for the general population. On the basis of these findings, Australian tobacco smoking cessation programs give recommendations for smoking cessation strategies for people with mental illnesses that are largely identical to recommendations given or people without mental illnesses; apart from warning about altered pharmacokinetics of some psychotropic medications, the possibility of withdrawal symptoms being mistaken for symptoms of mental illness and a risk of exacerbation of depressive symptoms. A government funded tobacco smoking cessation program in Brazil identifies people with mental illnesses; apart from warning about altered pharmacokinetics of some psychotropic medications, the possibility of withdrawal symptoms being mistaken for symptoms of mental illness and a risk of exacerbation of depressive symptoms. A government funded tobacco smoking cessation program in Brazil identifies people with mental illnesses and substance abuse and tailored their smoking cessation intervention to their needs. Kerr and colleagues describe barriers to mainstream tobacco smoking cessation programs for people with mental illnesses that include; perceived benefits of smoking to their symptoms of mental illness, fear of illness worsening, social circles where smokers predominate, low self-confidence, health professionals who are not encouraging their cessation efforts and are not trained in tobacco smoking cessation and reluctance to access mainstream smoking cessation services. Furthermore, health professionals are not always aware of the importance of addressing smoking cessation in this vulnerable group. While there is insufficient evidence to recommend any specific tobacco smoking cessation technique for people with bipolar disorder, there is sufficient evidence to conclude that tobacco smoking cessation interventions should be tailored to the individual needs and preferences of the person being treated. For some individuals with bipolar disorder mainstream tobacco smoking cessation techniques may be adequate. For other individuals it may be more effective to provide tobacco smoking cessation support delivered through their usual mental health care provider and providing support techniques additional to those provided by mainstream services. Health professionals should encourage smokers with mental illness to cease tobacco smoking.

**FUTURE DIRECTIONS FOR RESEARCH: TOBACCO SMOKING IN BIPOLAR DISORDER**

In this review, an attempt has been made to understand the relationship between smoking and bipolar disorder. As Pasco et al. note, it is becoming increasingly clear that tobacco smoking is not only harmful to our physical health, but also for our mental health, which may in fact contribute to its onset or aggravate current symptoms.

It is possible that certain individuals are more vulnerable to nicotine’s psychostimulant properties than others and researchers have implied that there is the possibility that separate causal mechanisms may operate in a bi-directional manner. Many of the studies evaluated did not assess for nicotine dependence, which may play a bigger role on nicotine’s effect on mood symptomatology that rates of daily smoking. It is also clear that more studies need to be conducted to accurately assess the consequences that dependent tobacco smoking places on bipolar disorder. It is suggested that consistent measures of mood symptoms as they apply to bipolar disorder are assessed, as well as consistent measures to assess nicotine dependence amongst individuals with bipolar disorder.

In conclusion, people with bipolar disorder have much higher tobacco smoking rates compared to the general population. Furthermore, although the relationship between tobacco smoking and bipolar disorder may be bidirectional and that cause and effect may be difficult to determine, the majority of studies reviewed suggest that tobacco smoking appears to play a mediating role in the severity of bipolar disorder. Clear gaps exist in the literature, and there is a need for researchers to look at formal smoking cessation programs and the relationship between tobacco smoking, insomnia, lifestyle factors and quality of life in bipolar disorder. Caggiula et al. suggest, the abuse liability associated with tobacco smoking equals or exceeds that of other addictive drugs. It is also suggested that tobacco smoking is screened by mental health professionals and targeted during routine treatment, with the implementation of more formal cessation programs.

**Acknowledgments**

Dr. Marta Rapado-Castro was supported by Sara Borrell Health Research Fellowship from the Institute of Health Carlos III, Spanish Ministry of Economy and Competitiveness, an Alicia Koplowitz Short-Term Fellowship and a IiSGM Fellowship Award for Short-term Placements from the Health Research Institute from the Hospital Gregorio Marañón (IiSGM) (Madrid, Spain).

**REFERENCES**


37. Chung JK, Lee KY, Kim SH, Kim EJ, Jeong SH, Jung HY,


48. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DB, Zarate CA Jr. 71. Caskey NH, Jarvik ME, Wirshing WC.


